icolung

icometrix

icolung is a cloud-based AI software to quantify the degree of lung involvement in COVID-19 patients. CE cleared, in the US available for clinical use during public health emergency related to COVID-19.

icolung provides the quantification of lung pathology in COVID-19 patients.
- Automated quantification
- Assessment of lesion burden
- Total and regional volumetrics in 6 pulmonary regions
- Quantification per type of CT finding (e.g. GGO, …)
Product specifications Information source: Vendor
Last updated: June 18, 2020
General
Product name icolung
Company icometrix
Subspeciality Chest
Modality CT
Disease targeted COVID-19
Key-features Quantification of lung involvement, total and lobular, lesion classification
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion
Data characteristics
Population all non-contrast chest CT images
Input non-contrast chest CT image
Input format DICOM
Output Color-coded segmentation overlays, report with quantification of lung involvement.
Output format DICOM
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform
Deployment Cloud-based
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes
Certification
CE Certified, Class I
FDA No or not yet
Market presence
On market since 04-2020
Distribution channels Siemens Teamplay
Countries present (clinical, non-research use) 17
Paying clinical customers (institutes) 75
Research/test users (institutes) 20
Pricing
Pricing model Pro bono
Based on Public need
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers https://icometrix.com/resources/the-role-of-imaging-ai--and--ct-in-covid19